Deutschmann K E, Peter H H, Schultheis W, Deicher H
Tumori. 1977 May-Jun;63(3):303-7. doi: 10.1177/030089167706300309.
Three years experience with post operative BCG adjuvant immunotherapy in stage II malignant melanoma is reported. Compared to a historical control group (35 cases), 23 melanoma patients showed a significantly improved remission duration and survival rate. It appears that patients with weak initial BCG reactions, which become gradually positive after several immunizations, get more benefit from the adjuvant immunotherapy than do patients with strongly positive initial BCG reactions.
报告了II期恶性黑色素瘤术后卡介苗辅助免疫治疗的三年经验。与历史对照组（35例）相比，23例黑色素瘤患者的缓解期和生存率有显著改善。似乎初始卡介苗反应较弱、经过几次免疫后逐渐转为阳性的患者，比初始卡介苗反应强阳性的患者从辅助免疫治疗中获益更多。
